Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Macey, Richard ^a   Walsh, Tanya ^a   Brocklehurst, Paul ^b   Kerr, Alexander R ^c   Liu, Joseph Ly ^d   Lingen, Mark W ^e   Ogden, Graham R ^d   Warnakulasuriya, Saman ^f   Scully, Crispian ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

^c NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF CHICAGO   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; CLINICAL FEATURE; CLINICAL PATHWAY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HUMAN; LIP DISEASE; MOUTH CANCER; MOUTH DISEASE; MOUTH EXAMINATION; MOUTH LESION; MOUTH SQUAMOUS CELL CARCINOMA; ORAL POTENTIALLY MALIGNANT DISORDER; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; SYSTEMATIC REVIEW; VITAL STAIN; BLOOD; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; DIAGNOSTIC USE; EARLY DIAGNOSIS; LIGHT; LIP NEOPLASMS; META ANALYSIS; MOUTH NEOPLASMS; PATHOLOGY; SALIVA;

COLORING AGENT; TUMOR MARKER;

CARCINOMA, SQUAMOUS CELL; COLORING AGENTS; EARLY DETECTION OF CANCER; HUMANS; LIGHT; LIP NEOPLASMS; MOUTH NEOPLASMS; SALIVA; TUMOR MARKERS, BIOLOGICAL;

EID: 84945330670     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010276.pub2     Document Type: Review

References (131)

1. Allegra E, Lombardo N, Puzzo L, Garozzo A. The usefulness of toluidine staining as a diagnostic tool for precancerous and cancerous oropharyngeal and oral cavity lesions [Utilità della colorazione con toluidina nella diagnosi delle lesioni precancerosee cancerose dellorofaringe e del cavo orale]. ACTA Otorhinolaryngologica Italica 2009;29:187-90.
2. Awan KH, Morgan PR, Warnakulasuriya S. Evaluation of an autofluorescence based imaging system (VELscope™) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncology 2011;47:274-7.
3. Awan KH, Yang YH, Morgan PR, Warnakulasuriya S. Utility of toluidine blue as a diagnostic adjunct in the detection of potentially malignant disorders of the oral cavity - a clinical and histological assessment. Oral Diseases 2012;18:728-33.
4. Cancela-Rodriguez P, Cerero-Lapiedra R, Esparza-Gomez G, Llamas-Martinez S, Warnakulasuriya S. The use of toluidine blue in the detection of pre-malignant and malignant oral lesions. Journal of Oral Pathology & Medicine 2010;40:300-4.
5. Chen Y-W, Lin J-S, Fong JH-J, Wang I-K, Chou S-J, Wu C-H, et al. Use of methylene blue as a diagnostic aid in early detection of oral cancer and precancerous lesions. British Journal of Oral and Maxillofacial Surgery 2007;45(7):590-1.
6. Cheng B, Yang L. The clinical evaluation of Oratest in detecting oral mucosal lesions. West China Journal of Stomatology 2003;21(2):124-6.
7. Cheng B, Yang L. The clinical evaluation of Oratest in detecting oral mucosal lesions. West China Journal of Stomatology 2003;21(2):124-6.
8. Delavarian Z, Mohtasham N, Mosannen-Mozaffari P, Pakfetrat A, Shakeri M-T, Ghafoorian-Maddah R. Evaluation of the diagnostic value of a Modified Liquid-Based Cytologyusing OralCDx Brush in early detection of oral potentially malignant lesions and oral cancer. Medicina Oral Patologia Oral y Cirugia Bucal 2010;Sep 1(15):e671-6.
9. Du GF, Li CZ, Chen HZ, Chen XM, Xiao Q, Cao ZG, et al. Rose bengal staining in detection of oral precancerous and malignant lesions with colorimetric evaluation: A pilot study. International Journal of Cancer 2007;120(9):1958-63.
10. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncology 2008;44:538-44.
11. Farah CS, McCullough MJ. A pilot case control study on the efficacy of acetic acid wash and chemiluminescent illumination (ViziLite) in the visualisation of oral mucosal white lesions. Oral Oncology 2007;43:820-4.
12. Farah CS, McIntosh L, Georgiou A, McCullough MJ. Efficacy of tissue autofluorescence imaging (Velscope) in the visualization of oral mucosal lesions. Head & Neck 2012 June;32(6):856-62.
13. Guneri P, Epstein JB, Kaya A, Veral A, Kazandy A, Boyacioglu H. The utility of toluidine blue staining and brush cytology as adjuncts in clinical examination of suspicious oral mucosal lesions. Oral and Maxillofacial Surgery 2011;40:155-66.
14. Gupta A, Singh M, Ibrahim R, Mehrotra R. Utility of toluidine blue staining and brush biopsy in precancerous and cancerous oral lesions. Acta Cytologica 2007;51(5):788-94.
15. Koch FP, Kunkel M, Biesterfeld S. Diagnostic efficiency of differentiating small cancerous and precancerous lesions using mucosal brush smears of the oral cavity-a prospective and blinded study. Clinical Oral Investigations 2011;15:763-9.
16. Koch FP, Kaemmerer PW. Effectiveness of autofluorescence to identify suspicious oral lesions-a prospective, blinded clinical trial. Clinical Oral Investigations 2011;15:975-82.
17. Leunig A, Betz CS, Mehlmann M, Stepp H, Arbogast S, Grevers G, et al. Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Laryngoscope 2000;110(1):78-83.
18. Mashberg A. Reevaluation of toluidine blue application as a diagnostic adjunct in the detection of asymptomatic oral squamous carcinoma: a continuing prospective study of oral cancer Ill. American Cancer Society 1980;4:758-63.
19. McIntosh L, McCullough MJ, Farah CS. The assessment of diffused light illumination and acetic acid rinse (Microlux/DL) in the visualisation of oral mucosal lesions. Oral Oncology 2009;45:e227-31.
20. Mehrotra R, Kumar Singh M, Pandya S, Singh M. The use of an oral brush biopsy without computer-assisted analysis in the evaluation of oral lesions: a study of 94 patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2008;106:246-53.
21. Mehrotra R, Singh M, Thomas S, Nair P, Pandya S, Shakti Nigam N, Shukla P. A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and cancerous oral lesions. Journal of the American Dental Association 2010;141:151-6.
22. Mehrotra R, Mishra S, Singh M, Singh M. The efficacy of oral brush biopsy with computer assisted analysis in identifying precancerous and cancerous lesions. Head & Neck Oncology 2011;3(39):1-7.
23. Mojsa I, Kaczmarzyk T, Zaleska M, Stypulkowska J, Zapala-Pospiech A, Sadecki D. Value of the ViziLite Plus System as a diagnostic aid in the early detection of oral cancer/premalignant epithelial lesions. Journal of Craniofacial Surgery 2012;23(2):162-4.
24. Nagaraju K, Prasad S, Ashok L. Diagnostic efficiency of toluidine blue with Lugol's iodine in oral premalignant and malignant lesions. Indian Journal of Dental Research 2010;21(2):218-23.
25. Navone R, Marsico A, Reale I, Pich A, Broccoletti R, Pentenero M, et al. Usefulness of oral cytology for the diagnosis of oral squamous dysplasia and carcinoma. Minerva Stomatologica 2003;53(3):77-86.
26. Navone R, Pentenero M, Rostan I, Burlo P, Marsico A, Broccoletti R, et al. Oral potentially malignant lesions: first-level micro-histological diagnosis from tissue fragments sampled in liquid-based diagnostic cytology. Journal of Oral Pathology & Medicine 2008;37:358-63.
27. Ng SP, Mann IS, Zed C, Doudkine A, Matisic J. The use of quantitative cytology in identifying high-risk oral lesions in community practice. Oral and Maxillofacial Pathology 2012;114(3):358-64.
28. Onizawa K, Saginoya H, Furuya Y, Yoshida H, Fukuda H. Usefulness of fluorescence photography for diagnosis of oral cancer. Oral and Maxillofacial Surgery 1999;28:206-210.
29. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surgery Oral Medicine Oral Pathology 2001;May:535-40.
30. Rahman F, Tippu SR, Khandelwal S, Girish KL, Manjunath BC, Bhargava A. A study to evaluate the efficacy of toluidine blue and cytology in detecting oral cancer and dysplastic lesions. Quintessence International 2012;43:51-9.
31. Remmerbach TW, Meyer-Ebrecht D, Aach T, Wurflinger T, Bell AA, Schneider TE, et al. Toward a multimodal cell analysis of brush biopsies for the early detection of oral cancer. Cancer Cytopathology 2009;June:228-35.
32. Scheer M, Neugebauer J, Derman A, Fuss J, Drebber U, Zoeller JE. Autofluorescence imaging of potentially malignant mucosa lesions. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiation and Endodontology 2011;111(5):568-77.
33. Scheifele C, Schmidt-Westhausen AM, Dietrich T, Reichart PA. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncology 2004;40(8):824-8.
34. Sciubba JJ. Computer-assisted analysis of the oral brush biopsy. Journal of the American Dental Association 1999;130:1445-57.
35. Seijas-Naya F, García-Carnicero T, Gandara-Vila P, Couso-Folgueiras E, Perez-Sayans M, Gandara-Vila R, et al. Applications of OralCDx methodology in the diagnosis of oral leukoplakia. Medicina Oral Patologia Oral y Cirugia Bucal 2012;1(17):5-9.
36. Sharwani A, Jerjes W, Salih V, MacRobert AJ, El-Maaytah M, Khalil HSM, et al. Fluorescence spectroscopy combined with 5-aminolevulinicacid-induced protoporphyrin IX fluorescence in detecting oral premalignancy. Journal of Photochemistry and Photobiology 2006;83:27-33.
37. Sharwani A, Jerjes W, Salih V, Swinson B, Bigio IJ, El-Maaytah M, et al. Assessment of oral premalignancy using elastic scattering spectroscopy. Oral Oncology 2006;42:343-9.
38. Silverman S, Migliorati C, Barbosa J. Toluidine blue staining in the detection of oral precancerous and malignant lesions. Oral Medicine 1984;April:379-82.
39. Svirsky JA, Burns JC, Carpenter WM, Cohen DM, Bhattacharyya I, Fantasia JE, et al. Comparison of computer-assisted brush biopsy results with follow up scalpel biopsy and histology. General Dentistry 2002;50(6):500-3.
40. Ujaoney S, Motwani MB, Degwekar S, Wadhwan V, Zade P, Chaudhary M, et al. Evaluation of chemiluminescence, toluidine blue and histopathology for detection of high risk oral precancerous lesions: A cross-sectional study. BMC Clinical Pathology 2012;12(6):1-7.
41. Upadhyay J, Rao NN, Upadhyay RB, Agarwal P. Reliability of toluidine blue vital staining in detection of potentially malignant oral lesions - time to reconsider. Asian Pacific Journal of Cancer Prevention 2011;12:1757-60.
42. Warnakulasuriya KAAS, Johnson NW. Sensitivity and specificity of OraScan toluidine blue mouthrinse in the detection of oral cancer and precancer. Journal of Oral Pathology and Medicine 1996;25:97-103.
43. Betz CS, Stepp H, Janda P, Arbogast S, Grevers G, Baumgartner R, et al. A comparative study of normal inspection, autofluorescence and 5-ALA-induced PPIX fluorescence for oral cancer diagnosis. International Jorunal of Cancer 2002;97(2):245-52.
44. Bhoopathi V, Kabani S, Mascarenhas AK. Low positive predictive value of the oral brush biopsy in detecting dysplastic oral lesions. Cancer 2009;115(5):1036-40.
45. Burkhardt A. A response to Sensitivity and Specificity of OralBrush Biopsy by Hohlweg-Majert et al. Cancer Investigation 2010;28(5):560-1.
46. Driemel O, Dahse R, Hakim SG, Tsioutsias T, Pistner H, Reichert TE, et al. Laminin-5 immunocytochemistry: a new tool for identifying dysplastic cells in oral brush biopsies. Cytopathology 2007;18(6):348-55.
47. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, et al. High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clinical Oral Investigations 2007;11:93-9.
48. Driemel O, Kunkel M, Hullmann M, Kleinsasser N, Staudenmaier R, Muller-Richter U, et al. Performance of conventional oral brush biopsies [Wertigkeit der konventionellen oralen Bürstenbiopsie]. HNO 2008;56:205-10.
49. Ebenezar J, Ganesan S, Aruna P, Muralinaidu R, Renganathan K, Saraswathy TR. Noninvasive fluorescence excitation spectroscopy for the diagnosis of oral neoplasia in vivo. Journal of Biomedical Optics 2012;17(9):97007.
50. Epstein JB, Fatahzadeh M, Matisic J, Anderson G. Exfoliative cytology and electron microscopy in the diagnosis of hairy leukoplakia. Oral Surgery Oral Medicine Oral Pathology 1995;79(5):565-9.
51. Gomez Serrano MT, Fernandez JMT, Bravo JM. Toluidine blue solution as diagnostic aid in oropharyngeal cancer [Azul de toldina en enjuagues, como auxiliar diagnostico de cancer orofaringeo]. Revista ADM 1989;46(1):29-35.
52. Hegde MC, Kamath PM, Shreedharan S, Dannana NK, Raju RM. Supravital staining: it's role in detecting early malignancies. Indian Journal of Otolaryngology and Head and Neck Surgery 2006;58(1):31-4.
53. Hohlweg-Majert B, Deppe H, Metzger MC, Schumm S, Hoefler H, Kesting MR, et al. Sensitivity and specificity of oral brush biopsy. Cancer Investigation 2009;27:293-7.
54. Jayaprakash V, Sullivan M, Merzianu M, Rigual NR, Loree TR, Popat SR, et al. Autofluorescence-guided surveillance for oral cancer. Cancer Prevention Research 2009;11(2):966-74.
55. Kulapaditharom B, Boonkitticharroen V. Laser-induced fluorescence imaging in localization of head and neck cancers. Annals of Otology, Rhinology & Laryngology 1998;107(3):241-6.
56. Lane P, Lam S, Follen M, MacAulay C. Oral fluorescence imaging using 405-nm excitation, aiding the discrimination of cancers and precancers by identifying changes in collagen and elastic breakdown and neovascularization in the underlying stroma. Gender Medicine 2012;9(1):S78-82.e8.
57. Levine TS, Njemenze V, Cowpe JG, Coleman FV. The use of PAPNET automated cytological screening system for the diagnosis of oral squamous carcinoma. Cytopathology 1998;9(6):398-405.
58. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, et al. Salivary transcriptome diagnostics for oral cancer detection. Clinical Cancer Research 2004;10(24):8442-50.
59. Majumder SK, Gupta A, Gupta S, Ghosh N, Gupta PK. Multi-class classification algorithm for optical diagnosis of oral cancer. Journal of Photochemistry and Photobiology 2006;85(2):109-17.
60. Mallia RJ, Narayanan S, Madhavan J, Sebastian P, Kumar R, Mathews A, ET AL. Diffuse reflection spectroscopy: an alternative to autofluorescence spectroscopy in tongue cancer detection. Applied Spectroscopy 2010;64(4):409-13.
61. Maraki D, Becker J, Boecking A. Cytologic and DNA-cytometric very early diagnosis of oral cancer. Journal of Oral Pathology and Medicine 2004;33:398-404.
62. Maraki D, Yalcinkaya S, Pomjanski N, Megahed M, Boecking A, Becker J. Cytologic and DNA-cytometric examination of oral lesions in lichen planus. Journal of Oral Pathology and Medicine 2006;35(4):227-32.
63. Navone R, Burlo P, Pich A, Pentenero M, Broccoletti R, Marsico A, ET AL. The impact of liquid-based oral cytology on the diagnosis of oral squamous dysplasia and carcinoma. Cytopathology 2007;18(6):356-60.
64. Navone R. Cytology of the oral cavity: a re-evaluation. Pathologica 2009;101:6-B.
65. Nieman LT, Kan CW, Gillenwater A, Markey MK, Sokolov K. Probing local tissue changes in the oral cavity for early detection of cancer using oblique polarized reflectance spectroscopy: a pilot clinical trial. Journal of Biomedical Optics 2008;13(2):24011-1.
66. Poate TWJ, Buchanan JAG, Hodgson TA, Speight PM, Barrett AW, Moles DR, et al. An audit of the efcacy of the oral brush biopsy technique in a specialist Oral Medicine unit. Oral Oncology 2004;40:829-34.
67. Ranaa M, Zapfb A, Kuehlea M, Gellrichaand NC, Eckardta AM. Clinical evaluation of an autofluorescence diagnostic device for oral cancer detection: a prospective randomized diagnostic study. European Journal of Cancer Prevention 2012;21(5):460-6.
68. Reboiras-López MD, Pérez-Sayáns M, Somoza-Martín JM, Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM, et al. Comparison of the Cytobrush, dermatological curette and oral CDx brush test as methods for obtaining samples of RNA for molecular analysis of oral cytology. Cytopathology 2011;23(3):192-7.
69. Remmerbach TW, Weidenbach H, Pomjanski N, Knops K, Mathes S, Hemprich A, et al. Cytologic and DNA-cytometric early diagnosis of oral cancer. Analytical Cellular Pathology 2001;22(4):211-21.
70. Remmerbach TW, Weidenbach H, Müller C, Hemprich A, Pomjanski N, Buckstegge B, et al. Diagnostic value of nucleolar organizer regions (AgNORs) in brush biopsies of suspicious lesions of the oral cavity. Analytical Cellular Pathology 2003;25(3):139-46.
71. Remmerbach TW, Mathes SN, Weidenbach H, Hemprich A, Bocking A. Noninvasive brush biopsy as an innovative tool for early detection of oral carcinomas [Nichtinvasive Bürstenbiopsie als innovative Methodein der Früherkennung des Mundhöhlenkarzinoms]. Mund Kiefer und GesichtsChirurgie 2004;8:229-36.
72. Remmerbach TW, Hemprich A, Bocking A. Minimalinvasive Burstenbiopsie [Minimalinvasive Burstenbiopsie]. Praxis Fortbildung 2007;117:926-40.
73. Sandler HC. Reliability of oral exfoliative cytology for detection of oral cancer. Journal of the American Dental Association 1964;68:489-99.
74. Schwarz RA1, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK, et al. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 2009 April;115(8):1669-79.
75. Shklar G, Cataldo E, Meyer I. Reliability of cytologic smear in diagnosis of oral cancer. A controlled study. Archives of Otolaryngology 1970;91(2):158-60.
76. Silverman S, Migliorati C. Toluidine blue staining and early detection of oral precancerous and malignant lesions. Iowa Dental Journal 1992;78(2):15-6.
77. Swider M, Nakwer K, Wierzbicki J, Grudzinska J. Toluidine test in the diagnosis of oral cancer. Czasopismo Stomatologiczne 1984;37(9):669-703.
78. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncology 2009;45:468-73.
79. Wang CY, Tsai T, Chiang CP, Chen HM, Chen CT. Improved diagnosis of oral premalignant lesions in submucous fibrosis patients with 5-aminolevulinic acid induced PpIX fluorescence. Journal of Biomedical Optics 2009;14(4):044026.
80. Bessell A, Glenny AM, Furness S, Clarkson JE, Oliver R, Conway DI, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD006205.pub3]
81. Bossuyt, PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Annals of Internal Medicine 2003;138(1):W1-12.
82. Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, et al. Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncology 2011;47(1):51-5.
83. Brocklehurst P, Kujan O, O'Malley LA, Ogden G, Shepherd S, Glenny AM. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD004150.pub3]
84. Buchen L. Cancer: Missing the mark. Nature 2011;471(7339):428-32.
85. Cancer Research UK. Oral cancer statistics. www.cancerresearchuk.org/cancer-info/cancerstats/types/oral (accessed 8 April 2011).
86. Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashibe M, Macpherson LM. Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies. International Journal of Cancer 2008;122(12):2811-9.
87. Divani S, Exarhou M, Theodorou LN, Georgantzis D, Skoulakis H. Advantages and difficulties of brush cytology in the identification of early oral cancer. Archive of Oncology 2009;17(1-2):11-2.
88. Faggiano F, Partanen T, Kogevinas M, Boffetta P. Socioeconomic differences in cancer incidence and mortality. In: Kogevinas M, Pearce N, Susser M, Boffetta P editor(s). Social Inequalities and Cancer. Lyon: IARC Scientific Publications No 138. International Agency for Research in Cancer, 1997.
89. Fedele S. Diagnostic aids in the screening of oral cancer. Head and Neck Oncology 2009;1:5.
90. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893-917.
91. Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD006386.pub3]
92. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005;293(10):1223-38.
93. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD006387.pub2]
94. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncology 2006;42(5):461-74.
95. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral Oncology 1997;33(5):302-12.
96. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-74.
97. Lee JM, Garon E, Wong DT. Salivary diagnostics. Orthodontics and Craniofacial Research 2009;12(3):206-11.
98. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine 2008;149(12):889-97.
99. Seoane Lestón J, Diz Dios P. Diagnostic clinical aids in oral cancer. Oral Oncology 2010;46(6):418-22.
100. Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. Journal of Clinical Oncology 2006;24(11):1754-60.
101. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncology 2008;44(1):10-22.
102. Liu JL, Wyatt JC, Deeks JJ, Clamp S, Keen J, Verde P, et al. Systematic reviews of clinical decision tools for acute abdominal pain. Health Technology Assessment 2006;10(47):1-167.
103. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD001829.pub3]
104. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from www.srdta.cochrane.org/handbook-dta-reviews.
105. Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S, Brasure J, et al. Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. European Journal of Cancer. Part B, Oral Oncology 1995;31B(3):181-7.
106. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia- A systematic review and meta-analysis. Head & Neck 2009;31(12):1600-9.
107. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. Journal of Oral Pathology and Medicine 2008;37(1):1-10.
108. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clinical Cancer Research 2009;15(17):5473-7.
109. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology 2001;2(9):533-43.
110. Patton LL, Epstein JB, Kerr AR. Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. Journal of the American Dental Association 2008;139(7):896-905.
111. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncology 2003;39(8):770-80.
112. Reibul J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Critical Reviews in Oral Biology and Medicine 2003;14(1):47-62.
113. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
114. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. Journal of the American Dental Association 2010;141(5):509-20.
115. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
116. Rosin M. Bringing the Promise of Molecular Medicine to Oral Cancer Screening. www.nidcr.nih.gov/Research/ResearchResults/InterviewsOHR/TIS032006.htm (accessed 18 April 2011).
117. Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA, Chen C. Survival and patterns of relapse in patients with oral tongue cancer. Journal of Oral and Maxillofacial Surgery 2010;68(3):584-9.
118. Scully C, Porter S. ABC of oral health. Oral cancer. BMJ 2000;321(7253):97-100.
119. Scully C, Shotts R. ABC of oral health. Mouth ulcers and other causes of orofacial soreness and pain. BMJ 2000;321(7254):162-5.
120. Scully C, Porter S. ABC of oral health. Swellings and red, white, and pigmented lesions. BMJ 2000;321(7255):225-8.
121. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncology 2009;45(4-5):301-8.
122. Stell PM, Wood GD, Scott MH. Early oral cancer: treatment by biopsy excision. British Journal of Oral Surgery 1982;20(4):234-8.
123. Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. Journal of Clinical Epidemiology 2000;53(5):477-84.
124. Tilley CJ, Chalkley MJ. Measuring access to health services: General Dental Services in Scotland. British Dental Journal 2005;199:599-601.
125. U.S. Preventive Services Task Force. Screening for Oral Cancer. http://www.uspreventiveservicestaskforce.org/uspstf/uspsoral.htm 2013.
126. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa: terminology, classification and present concepts of management. Oral Oncology 2009;45(4-5):317-23.
127. Walsh T, Liu JLY, Brocklehurst P, Glenny AM, Lingen M, Kerr AR, et al. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010173]
128. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology and Medicine 2007;36(10):575-80.
129. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncology 2009;45(4-5):309-16.
130. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
131. Wyatt JC, Altman DG. Commentary: Prognostic models: clinically useful or quickly forgotten?. BMJ 1995;311(7019):1539-41.